-
1
-
-
84990341089
-
Defending value and maximizing profitability of innovative pharmaceuticals over their entire life cycles
-
Bruce, L. (2003). Defending value and maximizing profitability of innovative pharmaceuticals over their entire life cycles. Int. J. Med. Market 3, 195-197.
-
(2003)
Int. J. Med. Market
, vol.3
, pp. 195-197
-
-
Bruce, L.1
-
2
-
-
24644483477
-
Start early, sell more, sell longer
-
Daly, R. & Kolassa, M. (2004). Start early, sell more, sell longer. Pharma. Exec. 1, 8-20.
-
(2004)
Pharma. Exec
, vol.1
, pp. 8-20
-
-
Daly, R.1
Kolassa, M.2
-
3
-
-
55749113824
-
Strategies for extending the life of patents
-
Spruill, M. W. & Cunningham, M. L. (2005). Strategies for extending the life of patents. BioPharm. Int. 18, 42-45.
-
(2005)
BioPharm. Int
, vol.18
, pp. 42-45
-
-
Spruill, M.W.1
Cunningham, M.L.2
-
4
-
-
84986132058
-
Surviving patient expiration: Strategies for marketing pharmaceutical products
-
Agrawal, M. & Thakkar, N. (1997). Surviving patient expiration: strategies for marketing pharmaceutical products. J. Product. Brand. Manage. 6, 305-314.
-
(1997)
J. Product. Brand. Manage
, vol.6
, pp. 305-314
-
-
Agrawal, M.1
Thakkar, N.2
-
5
-
-
55749113484
-
-
Fact sheet: TRIPS and pharmaceutical patents, (http://www.ppl.nl/ bibliographies/wto/files/6074.pdf). World Trade Organization, accessed 25th November, 2007.
-
Fact sheet: TRIPS and pharmaceutical patents, (http://www.ppl.nl/ bibliographies/wto/files/6074.pdf). World Trade Organization, accessed 25th November, 2007.
-
-
-
-
7
-
-
84990373748
-
Pricing policies to handle patent loss or expiry
-
Barak, A. & Wilson, G. (2003). Pricing policies to handle patent loss or expiry. Int. J. Med. Market. 3, 245-249.
-
(2003)
Int. J. Med. Market
, vol.3
, pp. 245-249
-
-
Barak, A.1
Wilson, G.2
-
8
-
-
0002815023
-
Exploit the product life cycle
-
Levitt, T. (1965). Exploit the product life cycle. Harvard Bus. Rev. 43, 81-93.
-
(1965)
Harvard Bus. Rev
, vol.43
, pp. 81-93
-
-
Levitt, T.1
-
9
-
-
84992924051
-
The art of using secondary patents to improve protection
-
Burdon, M. & Sloper, K. (2003). The art of using secondary patents to improve protection. Int. J. Med. Market. 3, 226-238.
-
(2003)
Int. J. Med. Market
, vol.3
, pp. 226-238
-
-
Burdon, M.1
Sloper, K.2
-
10
-
-
24644464917
-
Your patent is about to expire: What now?
-
Tuttle, E., Parece, A. & Hector, A. (2004). Your patent is about to expire: What now? Pharma. Exec. 24, 88-98.
-
(2004)
Pharma. Exec
, vol.24
, pp. 88-98
-
-
Tuttle, E.1
Parece, A.2
Hector, A.3
-
11
-
-
55749110998
-
-
Generic pharmaceutical association - commercial insights: antihypertensives, (http://www.datamonitor.com/), Datamonitor, accessed 5th September, 2007.
-
Generic pharmaceutical association - commercial insights: antihypertensives, (http://www.datamonitor.com/), Datamonitor, accessed 5th September, 2007.
-
-
-
-
12
-
-
55749104664
-
-
Lifecycle management in the pharmaceutical industry: The unexploited potential, (www.capgemini.com/lifesciences), Capgemini, accessed 3rd February, 2008.
-
Lifecycle management in the pharmaceutical industry: The unexploited potential, (www.capgemini.com/lifesciences), Capgemini, accessed 3rd February, 2008.
-
-
-
-
14
-
-
33846881807
-
Innovative marketing strategies after patent expiry: The case of GSK's antibiotic Clamoxyl in France
-
Chandon, P. (2004). Innovative marketing strategies after patent expiry: the case of GSK's antibiotic Clamoxyl in France. Int. J. Med. Market. 4, 65-73.
-
(2004)
Int. J. Med. Market
, vol.4
, pp. 65-73
-
-
Chandon, P.1
-
15
-
-
55749089094
-
The marketing of pharmaceuticals: Standardization or customization?
-
Doherty, G. & Ennew, C. T. (1995). The marketing of pharmaceuticals: standardization or customization? J. Market. Pract. 3, 39-50.
-
(1995)
J. Market. Pract
, vol.3
, pp. 39-50
-
-
Doherty, G.1
Ennew, C.T.2
-
16
-
-
33846958019
-
The fundamentals of standardizing global marketing strategy
-
Viswanathan, N. K. & Dickson, P. R. (2007). The fundamentals of standardizing global marketing strategy. Int. Market. Rev. 24 46-63.
-
(2007)
Int. Market. Rev
, vol.24
, pp. 46-63
-
-
Viswanathan, N.K.1
Dickson, P.R.2
-
18
-
-
34447109035
-
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension
-
Philipp, T., Smith, T. R., Glazer, R., Wernsing, M., Yen, J., Jin, J., Schneider, H. & Pospiech, R. (2007). Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther. 29, 563-580.
-
(2007)
Clin. Ther
, vol.29
, pp. 563-580
-
-
Philipp, T.1
Smith, T.R.2
Glazer, R.3
Wernsing, M.4
Yen, J.5
Jin, J.6
Schneider, H.7
Pospiech, R.8
-
19
-
-
55749113483
-
-
Assessing guidelines strategies and new drugs to get patients to target, (http://www.medscape.com/viewarticle/552438), Brookes, L., accessed 3rd February 2008.
-
Assessing guidelines strategies and new drugs to get patients to target, (http://www.medscape.com/viewarticle/552438), Brookes, L., accessed 3rd February 2008.
-
-
-
-
20
-
-
55749112804
-
-
Hatch, O. & Waxman, H. (1984). Drug price competition and patent term restoration act (Public Law 98-417). United States Federal Law.
-
Hatch, O. & Waxman, H. (1984). Drug price competition and patent term restoration act (Public Law 98-417). United States Federal Law.
-
-
-
-
21
-
-
8844235175
-
When form equals substance: The value of form screening in product life-cycle management
-
February
-
Lucas, J. & Burgess, P. (2004). When form equals substance: The value of form screening in product life-cycle management. Pharma Voice February, 54-57.
-
(2004)
Pharma Voice
, pp. 54-57
-
-
Lucas, J.1
Burgess, P.2
-
22
-
-
11244346687
-
Switching prescription drugs to over-the-counter
-
Cohen, J. P., Paquette, C. & Cairns, C. P. (2005). Switching prescription drugs to over-the-counter. BMJ 330, 39-41.
-
(2005)
BMJ
, vol.330
, pp. 39-41
-
-
Cohen, J.P.1
Paquette, C.2
Cairns, C.P.3
|